## 1 Drug-target Mendelian randomization analysis supports lowering plasma

## 2 ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing

## 3 cardiovascular disease risk

- 4 Fredrik Landfors<sup>1, 2, \*</sup>, Peter Henneman<sup>3</sup>, Elin Chorell<sup>1</sup>, Stefan K. Nilsson<sup>2, 4</sup>, Sander Kersten<sup>5, 6</sup>
- <sup>5</sup> <sup>1</sup> Department of Public Health and Clinical Medicine, Section of Medicine, Umea University, S-901
- 6 87 Umea, Sweden.
- <sup>7</sup> <sup>2</sup> Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden.
- <sup>8</sup> <sup>3</sup>Department of Human Genetics, Amsterdam University Medical Center, Meibergdreef 9, 1105 AZ,
- 9 Amsterdam, The Netherlands.
- <sup>4</sup> Department of Medical Biosciences, Umea University, S-901 87 Umea, Sweden.
- <sup>5</sup> Nutrition, Metabolism, and Genomics group, Division of Human Nutrition and Health, Wageningen
- 12 University, 6708WE, Wageningen, the Netherlands.
- <sup>6</sup> Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.
- <sup>\*</sup> To whom correspondence should be addressed.
- 15 Contact information for the corresponding author: Fredrik Landfors, Department of Public Health
- 16 and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email:
- 17 Fredrik.Landfors@umu.se; Phone: +46 (0) 70-454 92 08.

## 18 ABSTRACT

- 19 Background and Aims: APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that are actively
- 20 pursued as pharmacological targets to treat dyslipidemia and reduce the risk of atherosclerotic
- 21 cardiovascular disease. Here, we used human genetic data to compare the predicted therapeutic and
- 22 adverse effects of APOC3, ANGPTL3, and ANGPTL4 inactivation.
- 23 Methods: We conducted drug-target Mendelian randomization analyses using variants in proximity to
- 24 the genes associated with circulating protein levels to compare APOC3, ANGPTL3, and ANGPTL4 as
- 25 drug targets. We obtained exposure and outcome data from large-scale genome-wide association studies
- and used generalized least squares to correct for linkage disequilibrium-related correlation. We
- evaluated five primary cardiometabolic endpoints and screened for potential side effects across 694
- 28 disease-related endpoints, 43 clinical laboratory tests, and 11 internal organ MRI measurements.
- 29 *Results:* Genetically lowering circulating ANGPTL4 levels reduced the odds of coronary artery disease
- 30 (CAD) (odds ratio, 0.57 per s.d. protein [95%CI,0.47–0.70]) and type 2 diabetes (T2D) (odds ratio, 0.73
- 31 per s.d. protein [95%CI,0.57–0.94]). Genetically lowering circulating APOC3 levels also reduced the
- 32 odds of CAD (odds ratio, 0.90 per s.d. protein [95%CI,0.82–0.99]). Genetically lowered ANGPTL3
- 33 levels via common variants were not associated with CAD. However, meta-analysis of deleterious
- 34 variants revealed that *ANGPTL3* inactivation protected against CAD (odds ratio, 0.79 per allele [95%CI,
- 35 0.69–0.90]). Analysis of lowered ANGPTL3, ANGPTL4, and APOC3 levels did not identify important
- 36 safety concerns.
- 37 Conclusion: Human genetic evidence suggests that therapies aimed at reducing circulating levels of
- 38 ANGPTL3, ANGPTL4, and APOC3 reduce the risk of CAD. ANGPTL4 lowering may also reduce the
- risk of T2D.

## 40 STRUCTURED GRAPHICAL ABSTRACT

- 41 *Key Question:* Does human genetics support that triglyceride-lowering drugs targeting ANGPTL3,
- 42 ANGPTL4, and APOC3 will reduce the risk of cardiometabolic disease without causing side effects?
- 43 *Key Finding:* Genetically lowered circulating ANGPTL4 reduced coronary artery disease and type 2
- 44 diabetes risk. Genetically lowered ANGPTL3 and APOC3 also reduced coronary artery disease risk,
- 45 but no impact on type 2 diabetes risk was observed.
- 46 Take-home Message: Human genetics suggest that ANGPTL3, ANGPTL4, and APOC3-lowering
- 47 medications may prevent CAD. Medicines targeting ANGPTL4 may have added benefits for patients
- 48 with type 2 diabetes.

#### **GRAPHICAL ABSTRACT**



Graphical abstract summarizing the study's methods and findings.

Graphical abstract summarizing the overall study design. The 'Key Findings' figure provides a summary of the results

categorized into three groups. The term 'improves' denotes a statistically significant association with a clinically relevant effect magnitude. The term 'weak' refers to a statistically significant association with no clinically significant effect. 'ASCVD' denotes atherosclerotic cardiovascular disease. 'T2D' denotes type 2 diabetes.

## 55 INTRODUCTION

- 56 APOC3, ANGPTL3, and ANGPTL4 are circulating proteins that regulate plasma cholesterol and
- 57 triglyceride (TG) levels. They mainly act by inhibiting the enzyme lipoprotein lipase. All three proteins
- 58 are actively pursued as pharmacological targets to treat dyslipidemia and reduce the risk of
- 59 atherosclerotic cardiovascular disease. The inactivation of APOC3 using ASOs (Volanesorsen,
- 60 Olezarsen) has been shown to substantially reduce plasma TG levels in different patient groups with
- 61 severe hypertriglyceridemia (1). Volanesorsen is a second-generation ASO that was approved in Europe
- 62 for treating familial chylomicronemia syndrome. Olezarsen is a third-generation ASO that very recently
- 63 received fast-track designation from the FDA. Currently, several human trials are ongoing with an RNAi
- 64 against APOC3 called ARO-APOC3.
- 65 Similar to APOC3, the inactivation of ANGPTL3 using monoclonal antibodies (Evinacumab) (2-6),
- antisense oligonucleotides (ASOs) (Vupanorsen) (7, 8), and RNAi (ARO-ANG3) has been shown to
  significantly lower plasma LDL-C and TG levels in various dyslipidemic patients groups (9).
  Evinacumab was approved in 2021 as a treatment for homozygous familial hypercholesterolemia
  (HoFH), while Vupanorsen was discontinued in 2021 due to the limited reduction in non-HDL-C and
  TG and increases in liver fat and enzymes (10). Recent case reports suggest that Evinacumab may
- 71 promote the regression of atherosclerotic plaques in HoFH patients (11, 12).
- 72 Whereas the clinical development of anti-APOC3 and -ANGPTL3 treatments have progressed well,
- therapies targeting ANGPTL4 have faced delay because mice deficient in ANGPTL4 develop lethal
- 74 mesenteric lymphadenopathy and chylous ascites when fed a diet high in saturated fatty acids (13-15).
- 75 Whether whole-body inactivation of ANGPTL4 might trigger similar pathological features in humans
- 76 is unclear. As an alternative pharmacological strategy, inactivating ANGPTL4 specifically in the liver
- 77 holds considerable promise (16). Despite these challenges, targeting ANGPTL4 presents a promising
- 78 opportunity, as it may not only lower triglycerides and remnant cholesterol but also redirect lipids away
- from ectopic sites and towards adipose tissue, potentially protecting against type 2 diabetes (17).
- Human genetic data can be leveraged to predict the clinical effect of the pharmacological inactivation of genes or proteins. Here, we aimed to compare the predicted therapeutic effects of APOC3, ANGPTL3, and ANGPTL4 inactivation by investigating the biological and clinical impact of inactivation variants in the respective genes. In addition, to address safety concerns, we compared the predicted detrimental effects of APOC3, ANGPTL3, and ANGPTL4 inactivation on relevant disease
- 85 outcomes. We conclude that therapies specifically aimed at decreasing plasma ANGPTL3, ANGPTL4,
- 86 and APOC3 levels are expected to reduce the risk of coronary artery disease without raising safety
- 87 concerns. Therapies targeting ANGPTL4 levels are expected to favorably impact the risk of type 2
- 88 diabetes. This suggests that reducing ANGPTL4 could offer therapeutic advantages to a wider group of
- 89 patients with dyslipidemia and type 2 diabetes.

## 90 **METHODS**

## 91 Study design

- 92 The study was performed in four sequential steps as summarized in Figure 1. First, a two-sample
- 93 Mendelian randomization (MR) study was conducted to measure the association between ANGPTL3,
- 94 ANGPTL4, and APOC3 lowering with cardiometabolic diseases and risk factors. Second, two-sample
- 95 MR was conducted to measure the target proteins' association with phenotypes related to potential
- 96 adverse effects. Third, validation analyses were conducted to further assess the plausibility of the
- 97 findings obtained from steps 1-2. Lastly, to measure the association between profound genetic
- 98 inactivation of the target proteins and CAD, deleterious variant analyses in the UK Biobank were
- 99 performed and meta-analysed with previous studies.
- 100 Steps 1-2

## 101 Genetic instruments

- 102 To estimate the causal effects of pharmacologically inactivating the ANGPTL3, ANGPTL4, and
- 103 APOC3 genes, we performed two-sample drug-target MR. We used, as instrumental variables (IV),
- 104 genetic variants within 2.5 kilobase pairs (Kb) of the target gene that had genome-wide significant
- 105 associations (P-value  $\leq 5 \times 10^{-8}$ ) with protein abundance (called *cis* protein quantitative trait loci, *cis*-
- 106 pQTLs) or plasma TG, as determined by genome-wide association studies (GWAS). Variants
- 107 adjacent to the target genes were clumped at an LD threshold of  $r^2 \ge 0.10$  to avoid GLS-related
- 108 multicollinearity issues. Residual LD was accounted for using the generalized least squares (GLS)
- 109 IVW estimator described below.
- 110

## 111 Drug-target MR

The precision of the inverse-variance weighted (IVW) estimator can be influenced by LD-related correlation between the genetic IV in the drug target genes *cis* 'position. Therefore, we used a GLS IVW MR estimator to correct for this potential source of bias (18, 19). The GLS-corrected MR approach can be conceptualized as combining the independent information of variants near a target gene while maintaining robust standard errors through weighting for their LD-related correlation. Further information regarding Drug-target MR methodology, GLS, LD matrix sensitivity, and sample overlap

- 118 bias are found in the **Supplemental Methods**.
- 119 Due to the complex structure of the APOA1-APOA5-APOC3 locus, we supplemented the original 120 analyses with a second model of APOC3 lowering. In this model, APOC3 lowering was instrumented 121 through the APOC3 c.55+IG>A splice donor loss variant solely, as this variant is a high-confidence 122 predicted loss-of-function variant (gnomAD Genome Aggregation Database v.4.0.0, 123 https://gnomad.broadinstitute.org) independent of other common variants in this genomic region (20). 124 The APOC3 c.55+1G>A MRs used a Wald ratio estimator. Furthermore, we used LPL-adjacent and 125 genome-wide TG-associated variants as positive controls. LPL was analyzed using drug-target MR. For

126 the genome-wide TG-associated variant MR, we tested the causal effect of TG using variants in

127 chromosomes 1-22 associated with TG at P-value  $\leq 5 \times 10^{-8}$ . An LD clumping window of 500 Kb and a

128 threshold of  $r^2 \ge 0.001$  was applied before analysis using an IVW estimator.

## 129 Data sources

130 Plasma protein abundance was measured in GWAS using the SomaScan and Olink platforms (21, 22). 131 GWAS data on plasma TG, LDL cholesterol, HDL cholesterol, apolipoprotein B, apolipoprotein A1, 132 and lipoprotein(a) were retrieved from the 2018 Neale Lab UK biobank analysis 133 (http://www.nealelab.is/uk-biobank/). For the functional variant analyses, genetic association data on 134 TG, LDL cholesterol, and HDL cholesterol were retrieved from the AstraZeneca UK biobank exome 135 sequencing-based phenome-wide association study (PheWAS) portal (23). We obtained outcome 136 summary data from GWAS of six cardiometabolic disease endpoints, 16 cardiometabolic risk markers, 137 43 routine clinical chemistry tests, 11 internal organ MRI measurements, and five abdominal 138 lymphadenopathy-related phenotypes (see Table 1, Supplemental Table 1, and Supplemental 139 Methods). Phenome-wide MR analyses were conducted in FinnGen and the UK biobank. FinnGen 140 integrates genotype data from Finnish biobanks with longitudinal health registry data (24). The UK Biobank is a large-scale research resource containing genetic, blood chemistry, imaging, and health 141 142 record data from half a million UK participants (25). The FinnGen data freeze 10 and UK biobank meta-143 analysis (https://public-metaresults-fg-ukbb.finngen.fi) stores genetic association statistics on 694 144 disease-related outcomes from 301,552-882,347 individuals. Further details on the selection of GWAS 145 and the definition of exposures and outcomes are given in the Supplemental Methods.

## 146 Colocalization analyses

147 Drug-target MR substantially relies on the assumption that LD (a phenomenon in which neighboring 148 genetic variants are inherited together more frequently than anticipated by chance (26)) does not 149 confound the association between variant and outcome. In cases where there are distinct genetic variants 150 affecting both the exposure and the outcome, and they are connected through LD, there is a risk of 151 making incorrect conclusions (27). To limit this issue, we performed colocalization analyses, which test 152 whether two independent association signals in the same gene region are consistent with having a single 153 shared causal variant (that is, testing if the association signals are 'colocalized') (28). To assess possible 154 confounding from LD, all drug target MR analyses were complemented by colocalization analysis of 155 the 500 Kb (±250 Kb) region surrounding each target gene (28). Further details regarding the 156 colocalization analyses are provided in the Supplemental Methods.

157

## 158 Lymphadenopathy and phenome-wide MR analyses

159 A Wald ratio estimator was used for the single-variant MR of lymphadenopathy-related phenotypes and

160 the phenome-wide MR conducted in FinnGen (29). The variants were selected based on being within

- 161 2.5 Kb of the drug target gene, their strength of association with target protein plasma abundance ( $P \le$
- 162  $5 \times 10^{-8}$ ), their strength of association with triglyceride levels (P  $\leq 5 \times 10^{-8}$ ), availability, and their
- 163 functional consequence. For further details regarding genetic instrument justification for the phenome-
- 164 wide MRs, see the **Supplemental Methods**.



#### 165 166 167 168 169

Figure 1. Study design flow chart summarizing the objective, methods, and results.

'LD' indicates linkage disequilibrium. 'n.s.' denotes not significant. 'LPL' indicates lipoprotein lipase. 'MR' indicates Mendelian Randomization. 'EL' indicates endothelial lipase. 'CAD' indicates coronary artery disease. 'IVW' indicates inverse-variance weighted.

## 170

## Table 1. Description of GWAS data sets

	No	Trait	First author (year)	Consortium	Sample size (events/total)	Population
pQTL	1	Plasma protein abundance (SomaScan)	Ferkingstad (2021) (21)	deCODE	35,559	Icelandic
	2	Plasma protein abundance (Olink)	Dhindsa (2023) (22)	Not available	50,829	British
Diseases	3	Coronary artery disease	Aragam (2022) (30)	CARDioGRAMplusC4D; EPIC-CVD	181,522 / 1,165,690	European
	4	Chronic kidney disease	Wuttke (2019) (31)	CKDGen	41,395 / 480,698	European
	5	Ischemic stroke	Mishra (2022) (32)	GIGASTROKE	62,100 / 1,296,908	European
	6	Non-alcoholic fatty liver disease	Ghodsian (2021) (33)	Not available	8,434 / 787,048	European
	7	Type 2 diabetes	Mahajan (2018) (34)	DIAGRAM	74,124 / 898,130	European
Risk factors	8	Plasma total, HDL, and LDL cholesterol; Apolipoprotein B; Apolipoprotein A1; TG; Lipoprotein(a); HbA1c	Neale lab (2018)	Not available	273,896 - 344,278;	British
	9	HDL, and LDL cholesterol; TG; NMR metabolomics	Wang (2021) (23); Nag (2023) (35)	AZPheWAS	95,077 – 376,311	British
	10	NMR metabolomics, including total lipoprotein phospholipids	Elsworth (2020) (36)	MRC-IEU	110,058 – 115,078	British
	11	Systolic blood pressure; diastolic blood pressure	Evangelou (2018) (37)	Not available	757,601	European
	12	Body mass index; waist-hip ratio	Pulit (2018) (38)	GIANT	694,649 – 806,834	European
	13	Body fat percentage; NMR total triglycerides; NMR total phospholipids	Elsworth (2020) (36)	MRC-IEU	115,078 – 454,633	British
	14	Plasma creatinine estimated glomerular filtration rate (eGFR); cystatin C eGFR	Stanzick (2021) (39)	CKDGen	1,004,040; 1,201,909	European; 86% European
Safety- related	15	Magnetic resonance imaging of internal organs	Liu (2021) (40)	Not available	25,617 - 32,860	British
	16	Routine blood chemistry tests	Neale lab (2018)	Not available	30,565 – 350,812	British
	17	Acute lymphadenitis; Acute peritonitis; Ascites; Intestinal malabsorption; Non-infectious lymphatic disorders	Neale lab (2018); Kurki (2023) (24)	Not available; FinnGen	620 - 4,982 / 270,172 - 382,633; 798 - 1643 / 295,812 - 341,350	British; Finnish
	18	Phenome-wide association study	FinnGen (2023) (24)	Pan-UK Biobank + FinnGen meta-analysis	110 – 279,543 / 301,552 – 882,347	British; Finnish

'NMR' indicates nuclear magnetic resonance spectroscopy.

## 172 Step 3

## 173 Genetic mimicry analyses

174 Genetic mimicry analysis was used to compare the metabolic concordance between common and 175 deleterious variants adjacent to the ANGPTL3, ANGPTL4, and APOC3 genes. This method uses linear 176 regression to determine the extent of similarity between different variants' genetic associations in high-177 dimensional data sets (41, 42). The degree of concordance was reported as the coefficient of 178 determination ( $\mathbb{R}^2$ ). Genetic associations between the common variants and 167 plasma metabolites were 179 measured by drug-target MR with plasma TGs as the exposure using data sets 8 and 10 (see Table 1). 180 Deleterious variants were defined as any protein-truncating variant with an allele frequency <0.05 or 181 missense variants with a REVEL pathogenicity prediction score >0.25 and allele frequency <0.00025 182 (see **Supplemental methods**). The effects of deleterious variants were determined by regressing plasma 183 concentration of metabolites on deleterious variant carrier status in 181,672 UK Biobank participants 184 (see Supplemental Methods for details).

185

## 186 **Robustness checks and sensitivity analyses**

187 We performed sensitivity MR analyses of ANGPTL3, ANGPTL4, APOC3, LPL, and LIPG on CAD by 188 restricting the genetic instrument selection to variants within these target genes predicted to have 189 functional impacts. This strategy aimed to mitigate potential biases arising from common non-coding 190 small-effect variants outside the target genes, which could be confounded due to linkage disequilibrium 191 with other genes in the same genomic region. Ensembl Variant Effect Predictor (VEP) version 109 (43) 192 was used to annotate variants within 2.5 Kb of the target gene associated ( $P \le 0.01$ ) with target protein 193 levels and plasma triglycerides. Non-coding variants outside of the 5' untranslated region (UTR), 3' 194 UTR, or splice site regions were filtered out and excluded from further analysis, as were missense 195 variants lacking SIFT deleterious or PolyPhen likely or probably damaging annotations. MR was 196 conducted for single variants using the Wald ratio estimator, and meta-analysis was performed using a 197 random-effects IVW estimator.

## 198 Step 4

## 199 Meta-analysis of the impact of deleterious variants on CAD

200 We conducted genetic association analyses in the UK Biobank (see Supplemental Methods) and meta-201 analyzed the results with previous studies to assess how deleterious variants in ANGPTL3, ANGPTL4, 202 and APOC3 impact CAD risk. To minimize the influence of incorrect genotype calls for rare variants, 203 the meta-analysis was limited to studies where genotypes were determined by DNA sequencing. When 204 multiple papers reported on individuals from overlapping cohorts or case-control studies, we selected 205 the substudy with the largest sample size for inclusion in the meta-analysis. The meta-analyses were 206 restricted to European ancestries. We determined the impact of the inactivating variants on CAD risk 207 per mmol/L reduction of TG and per inactivating allele using fixed-effect IVW estimators. If no within-

sample association of inactivating variants with TG concentrations (in mmol/L) was available, the combined IVW meta-analysis TG estimate was used as the denominator to determine the CAD odds per mmol/L TG effect. Statistical heterogeneity across studies was estimated by calculating the Cochran Q

- 211 statistic.
- 212

## 213 Statistics

## 214 Multiple testing

215 P-values and 95% confidence intervals (CI) are reported using analysis-type Bonferroni multiple 216 comparisons correction. In the primary MR analyses, we corrected for the five cardiometabolic disease 217 outcomes that were run across three different drug-target gene exposures (ANGPTL3, ANGPTL4, 218 APOC3) for protein abundance, and four genes for the TG exposure (ANGPTL3, ANGPTL4, APOC3, 219 LPL). Additionally, we included five genome-wide triglyceride MR models, totaling 40 comparisons 220 for the cardiometabolic disease outcomes. In the cardiometabolic risk factor MR analyses of *cis*-pQTLs, 221 we made corrections for 45 multiple comparisons ( $15 \times 3$ ). Similarly, imaging and blood chemistry MR 222 analyses were corrected for 33 (11×3), and 129 (43×3) multiple comparisons, respectively. We did not 223 perform multiple comparison corrections for the ANGPTL4-targeted MR analyses of the 224 lymphadenopathy-related phenotypes. This was because identifying potential safety concerns that 225 needed to be addressed was considered more critical than stringent multiplicity correction for these 226 specific outcomes. Similarly, the primary motivation for performing the functional variant-limited CAD 227 MR analyses and deleterious variant meta-analysis was to reduce the risk of false-negative findings. 228 Additionally, we wanted to ensure that these CIs and P-values remained comparable across different 229 studies. These CIs and P-values were, therefore, not corrected for multiple comparisons. The 230 significance threshold in the phenome-wide cis-pQTL MR analyses was set at 2082 multiple 231 comparisons (694 phenotypes in the FinnGen R10 and UK biobank meta-analysis, times three genes).

## 232 **RESULTS**

- 233 The results of the drug-target MR analyses of cardiometabolic diseases, cardiometabolic risk factors,
- and the safety-related endpoints are presented in Figure 2, Figure 3, and Figure 4, respectively. MR
- scatter, colocalization plots, and results tables with greater detail are provided in Supplemental Figures
- 236 1-2 and Supplemental Table 2. Detailed PheWAS results are provided in Supplemental Tables 6-9.
- 237 The genetic variants selected for inclusion as instrumental variables in one or more of the MR analyses
- are shown in **Table 2**.

Table 2. G	Genetic instrum	nents		Effect (P-value)						
	rsID	Variant	HGVS	Consequence	Frequency	Protein (SomaScan)	Protein (Olink)	Protein (ELISA)‡	TG	
ANGPTL3	rs79151558	1:62595131:A>G		Upstream variant	0.028	-0.32 (8.1e-39)	-0.27 (1.4e-	-	-0.06 (5.4e-	
	rs11207997*	1:62596235:C>T		Upstream variant	0.338	-0.22 (1.2e-144)*	-0.31 (<2e- 308)*	-	-0.08 (2.7e- 221)*	
	rs17123728	1:62602628:G>A	c.931+248G>A	Intron variant	0.04	n.s.	-	-	0.03 (2.5e- 08)	
	rs35285100	1:62603486:T>C	c.932-483T>C	Intron variant	0.071	0.10 (2.3e-09)	0.08 (6.3e- 10)	-	n.s.	
	rs10789117*	1:62606594:A>C		Downstream variant	0.354	-0.22 (1.7e-144)*	-0.31 (<2e- 308)*	-	-0.08 (1.6e- 221)*	
	rs6678483*	1:62608771:C>A		Downstream variant	0.354	-0.22 (1.7e-144)*	-0.31 (<2e- 308)*	-	-0.08 (2e- 221)*	
ANGPTL4	rs116843064‡	19:8364439:G>A	p.Glu40Lys‡	Missense variant <sup>‡</sup>	0.024	-0.32 (6.6e-35)	-0.35 (6.8e- 48)	-0.45 (4.8e- 05)‡	-0.21 (3.2e- 127)	
	rs149480839	19:8368237:C>T	c.548-982C>T	Intron variant	0.03	n.s.	-	-	-0.05 (2.6e- 14)	
	rs139469000	19:8376253:C>T		Downstream variant	0.28	n.s.	-	-	-0.02 (1.7e- 09)	
APOC3	rs2727788	11:116828247:C>A		Upstream variant	0.262	n.s.	-	-	-0.05 (7.3e- 83)	
	rs138326449	11:116830638:G>A	c.55+1G>A	Splice donor variant	0.002	-2.19 (3.2e-142)	-	-	-0.86 (3.4e- 157)	
	rs5141†	11:116831407:T>C	c.179+511T>C	Intron variant	0.916	-0.17 (2.1e-38)†	-	-	-0.19 (<2e- 308) <sup>†</sup>	
	rs5132	11:116832062:C>T	c.180-702C>A	Intron variant	0.015	n.s.	-	-	0.06 (3.1e- 08)	
	rs12721031	11:116833789:C>T		Downstream variant	0.023	n.s.	-	-	-0.06 (2.6e- 12)	
	rs10750098†	11:116834852:G>T		Downstream variant	0.115	-0.17 (2.1e-38)†	-	-	-0.19 (<2e- 308)†	
	rs12721028	11:116834874:A>G		Downstream variant	0.159	n.s.	-	-	0.04 (2e- 35)	
	rs12718462	11:116835003:T>C		Downstream variant	0.066	n.s.	-	-	-0.05 (1.8e-	

Showing the genetic variants selected for inclusion as instrumental variables in one or more of the MR analyses whose results are shown in **Figures 2-4**. The specific instruments used in each separate MR analysis are provided in **Supplemental Table 2**. *Cis*-pQTLs meeting the significance threshold (P-value  $\leq 5 \times 10^{-8}$ ) were initially identified in the SomaScan protein GWAS. These cis-pQTLs were then cross-referenced with the UK Biobank Olink protein GWAS to determine if the effect estimates were consistent. Variant consequences were retrieved from the Ensembl Variant Effect Predictor (version 109) (43). 'Effect' indicates

the 1 s.d. protein abundance (retrieved from (21, 22)) or mmol/L TG change (retrieved from <u>http://www.nealelab.is/uk-biobank/</u>) per allele. 'rsID' denotes Reference single nucleotide polymorphism ID. 'HGSV' indicates Human Genome Structural Variation Consortium nomenclature for sequence variants. 'n.s.' indicates not significant.

\*<sup>†</sup> These variants were in strong linkage disequilibrium (LD) and, therefore, showed the same associations with TG levels and plasma ANGPTL3/APOC3 abundance. Because they were in strong LD, they were never included in the same MR model (see Methods and Supplemental Table 2).

<sup>±</sup> The association between ANGPTL4 p.E40K coding variant carrier status and plasma ANGPTL4 protein was confirmed in a separate study by ELISA using antibodies that were shown by Western blotting to similarly detect wildtype ANGPTL4 and ANGPTL4 containing the E40K substitution, indicating that the association was not attributable to epitope-binding artifacts (see Supplemental Methods).

## 254 Step 1

## 255 Drug-target MR of cardiometabolic diseases

- 256 Genetically mediated changes in plasma ANGPTL3 protein abundance were not associated with a
- 257 reduced risk of any cardiometabolic outcome (Figure 2A), nor were ANGPTL3-mediated changes in
- 258 plasma TG (**Figure 2B**).
- 259 The p.E40K coding variant was the only variant that qualified as a *cis*-pQTL in the *ANGPTL4* region.
- 260 ANGPTL4 p.E40K is a common missense variant (allele freq. ~2% in Europeans) that destabilizes
- ANGPTL4 after secretion and prevents ANGPTL4 from inhibiting LPL (44). The association between
- 262 the ANGPTL4 p.E40K coding variant and plasma ANGPTL4 protein was validated via ELISA in a
- 263 separate cohort. The association was -0.45 s.d. protein per allele, P=4.8×10<sup>-5</sup>, comparable to the
- associations detected with the Olink and Somascan platforms (see **Table 2**). The ELISA antibodies
- 265 detected wild-type and E40K ANGPTL4 proteins to a comparable degree, as determined by Western
- blot analysis (see Supplemental Methods for details). This suggests that the observed association was
   not attributable to epitope-binding artifacts.
- 268 Changes in ANGPTL4 protein levels via ANGPTL4 p.E40K were associated with a decreased risk of
- 269 CAD (OR: 0.57, P=1×10<sup>-19</sup>), and T2D (OR: 0.73, P=0.001) (Figure 2A). Similarly, changes in plasma
- 270 TG levels via three ANGPTL4-adjacent variants were associated with a decreased risk of CAD (OR:
- 271 0.43,  $P=1\times10^{-21}$ ), and T2D (OR: 0.62,  $P=4\times10^{-4}$ ) (Figure 2B). In addition, colocalization analyses
- 272 indicated a high probability of ANGPTL4 p.E40K being a shared causal variant for ANGPTL4 levels
- and TG levels with CAD and T2D (pp.H<sub>4</sub>: 98–100%) (Figures 2A-B).
- 274 Changes in APOC3 levels caused by APOC3-adjacent variants were associated with a reduced risk of
- 275 CAD (OR: 0.90, P=0.009) (Figure 2A), as were changes in TG levels through *APOC3*-adjacent variants
- 276 (OR: 0.80,  $P=4\times10^{-11}$ ). The APOC3 c.55+1G>A splice donor loss variant had a substantial impact on
- 277 plasma APOC3 levels (-2.19 s.d. protein,  $P=3.2\times10^{-142}$ ) and plasma TG (-0.86 mmol/L,  $P=3.4\times10^{-157}$ )
- 278 (Table 2). When compared to the model allowing for multiple variants in the *APOC3* region, APOC3
- 279 lowering modeled through the APOC3 c.55+1G>A variant demonstrated a comparable correlation with
- 280 CAD in terms of the direction of its effect. However, the association was non-significant (Figure 2).
- 281 Similar to APOC3 and ANGPTL4, changes in plasma TG levels through LPL-adjacent variants were
- associated with a reduced risk of CAD (OR: 0.69,  $P=1\times10^{-24}$ ), NAFLD (OR: 0.66, P=0.021), and T2D
- 283 (OR: 0.73, P=6×10<sup>-10</sup>) (**Figure 2B**).
- 284

### **Cardiometabolic diseases**

#### A. Exposure: Target protein abundance

Outcome	Events/Total	N	o. S
Coronary artery		ANGPTL3	3
disease	181,522 / 1,165,690	) ANGPTL4	1
uisease		APOC3	2
		APOC3 c.55+1G>A	1
Chronic kidnev		ANGPTL3	3
disease	41,395 / 480,698	3 ANGPTL4	1
4100400		APOC3	1
		APOC3 c.55+1G>A	0
	,	ANGPTL3	3
Ischemic stroke	62,100 / 1,296,908	3 ANGPTL4	1
		APOC3	1
		APOC3 c.55+1G>A	0
Non-alcoholic fa	tty a rat / Jaz a r	ANGPTL3	3
liver disease	3 8,434 / 787,048	3 ANGPTL4	1
		APOC3	1
		APOC3 c.55+1G>A	0
<b>T</b> 0		ANGPTL3	3
Type 2 diabetes	74,124 / 898,130	) ANGPIL4	1
		APOC3	2
		APUC3 C.55+1G>A	1

SNPs	Odds ratio (95% CI)	P-value	Coloc.
3 🗕	0.98 (0.91;1.06)	1.00	H1: 93%
1	0.57 (0.47:0.69)	1e-19	H4: 100%
2 -	0.90 (0.83:0.99)	0.009	H3: 100%
1 -	0.94 (0.84;1.04)	1.00	
3	0.97 (0.84;1.12)	1.00	H1: 94%
1	0.99 (0.68;1.44)	1.00	H1: 94%
1	0.86 (0.63;1.17)	1.00	H1: 95%
0			
3	1.08 (0.97;1.21)	0.66	H1: 95%
1	0.78 (0.57;1.08)	0.54	H1: 74%
1	0.97 (0.77;1.23)	1.00	H1: 94%
0			
3	1.05 (0.82;1.36)	1.00	H1: 97%
1	1.07 (0.61;1.87)	1.00	H1: 93%
1	0.91 (0.55;1.53)	1.00	H1: 94%
0	,		
3 +-	1.00 (0.91;1.11)	1.00	H1: 90%
1	0.73 (0.58;0.93)	0.001	H4: 98%
2 -	1.00 (0.90;1.11)	1.00	H3: 57%
1	1.08 (0.95;1.21)	1.00	
0.25 0.5 1 2	4		
Odds ratio per s.d. lowered protein abundance (95	5% CI)		

#### **B.** Exposure: Triglycerides

ANGPTL3 3	0.96 (0.78;1.18)	1.00	H1: 96%
ANGPTL4 3 -	0.43 (0.33;0.57)	1e-21	H4: 100%
181,522 / 1,165,690 APOC3 7	: 0.80 (0.72;0.89)	4e-11	H4: 100%
disease APOC3 c.55+1G>A 1	0.85 (0.65;1.12)	1.00	
LPL 20	0.69 (0.61;0.77)	1e-24	H3: 100%
Genome-wide TG QTLs 117	0.76 (0.69;0.84)	8e-19	
ANGPTL3 3	0.85 (0.57;1.27)	1.00	H1: 94%
Chronic kidnov ANGPTL4 3	0.97 (0.57;1.67)	1.00	H1: 94%
41,395 / 480,698 APOC3 6	0.85 (0.68;1.05)	0.53	H1: 95%
disease APOC3 c.55+1G>A 0	:		
<i>LPL</i> 19	0.92 (0.74;1.14)	1.00	H1: 94%
Genome–wide TG QTLs 95	<b>_+</b> − 1.00 (0.88;1.13)	1.00	
ANGPTL3 3	1.21 (0.89;1.63)	1.00	H1: 94%
ANGPTL4 3	0.74 (0.47;1.17)	1.00	H1: 74%
Ischemic stroke 62,100 / 1,296,908 APOC3 6	0.99 (0.85;1.16)	1.00	H1: 95%
<b>APOC3 c.55+1G&gt;A</b> 0			
<i>LPL</i> 14	0.97 (0.82;1.15)	1.00	H1: 96%
Genome–wide TG QTLs 89		1.00	
ANGPTL3 3	1.14 (0.56;2.31)	1.00	H1: 97%
Non-alcoholic fatty ANGPTL4 3	1.05 (0.46;2.39)	1.00	H1: 93%
liver disease 8,434 / 787,048 APOC3 5	0.96 (0.68;1.37)	1.00	H1: 95%
APOC3 c.55+1G>A 0			
<i>LPL</i> 14		0.021	H3: 52%
Genome–wide TG QTLs 83	0.92 (0.68;1.23)	1.00	
ANGPTL3 3	1.01 (0.77;1.32)	1.00	H1: 95%
ANGPTL4 3	0.62 (0.44;0.88)	4e-04	H4: 98%
Type 2 diabetes 74,124 / 898,130 APOC3 7	0.89 (0.78;1.01)	0.11	H3: 58%
APOC3 c.55+1G>A 1	1.20 (0.89;1.63)	1.00	
L <b>PL</b> 19	0.73 (0.63;0.85)	6e-10	H3: 51%
Genome-wide TG QTLs 104	0.87 (0.70;1.08)	1.00	
0.25	0.5 1 2 4		
Odds rati	o per mmol/L lowered triglycerides (95% CI)		

285

#### 286 Figure 2. Results of MR analyses of cardiometabolic disease outcomes.

287 A: Forest plot and table of the cis-pQTL-based MR analyses. 'Events/total' indicates the outcome study's case count and total sample size. 'No. SNPs' specifies the number of variants included in the MR model. Zero SNPs indicate that none of the 289 290 genetic instruments were detected in the outcome data set. 'Coloc.' shows the colocalization hypothesis (H<sub>0-4</sub>) with the highest posterior probability (see the 'Methods' section for details about their interpretation). B: Results of the MR analysis using TG levels as the exposure. The 'Genome-wide TG QTLs' and 'LPL' models were positive controls. 'Genome-wide TG QTLs' indicate the MR model that included independent (r<sup>2</sup> < 0.001, 500Kb clumping window) variants associated with TG levels  $\overline{293}$ (P≤5×10-8) across chromosomes 1-22. 'LPL' denotes lipoprotein lipase.

## 294 Drug-target cis-pQTL MR of cardiometabolic risk factors

- 295 Genetically lowered plasma ANGPTL3 levels were associated with reduced total cholesterol (-0.27
- 296 mmol/L, P=2×10<sup>-107</sup>), TG (-0.34 mmol/L, P=6×10<sup>-206</sup>), LDL-C (-0.15 mmol/L, P=2×10<sup>-57</sup>), ApoB (-0.03
- 297 g/, P=3×10<sup>-36</sup>), and ApoA-I levels (-0.05 g/L, P=1×10<sup>-51</sup>), while the effect on HDL-C was comparatively
- 298 weak (-0.02 mmol/L,  $P=4\times10^{-5}$ ) (Figure 3).
- 299 Genetically lowered plasma ANGPTL4 levels instrumented through the p.E40K variant were associated
- 300 with reduced plasma TG (-0.65 mmol/L,  $P=1\times10^{-125}$ ) and weakly reduced ApoB levels (-0.02 g/L,
- 301 P=0.038), as well as increased ApoA1 (0.11 g/L, P=1×10<sup>-55</sup>) and HDL-C levels (0.24 mmol/L, P=7×10<sup>-</sup>
- 302 <sup>134</sup>) (Figure 3). Genetically lowered plasma ANGPTL4 levels were also associated with modest
- reductions in the waist-hip ratio (-0.09 s.d., P=0.004), and a small increase in body fat percentage (0.07
- 304 s.d., P=0.008) (Figure 3).
- 305 Genetically lowered plasma APOC3 levels were associated with reduced TG levels (-0.58 mmol/L, P <
- 306  $2 \times 10^{-308}$ ) (Figure 3). APOC3 levels were also associated with ApoB (-0.03 g/L, P=1×10<sup>-22</sup>), LDL-C (-
- 307 0.10 mmol/L, P=6×10<sup>-18</sup>), HDL-C (0.16 mmol/L, P =  $2 \times 10^{-238}$ ), and total cholesterol (-0.08 mmol/L,
- $308 P=5 \times 10^{-6}$ ) (Figure 3). In terms of association and effect directionality, these results closely resembled
- 309 those of the *APOC3* c.55+1G>A model (Figure 3).

Outcome	Sample s	ize No	o. SNI	S	Effect (95% CI)	P-value	Coloc.
Total cholesterol	344,278	ANGPTL3 ANGPTL4 APOC3	3 1 2		- 0.27 (-0.31;-0.23) 0.09 (-0.01;0.18) - 0.08 (-0.12;-0.03)	2e-107 0.19 5e-06	H3: 100% H3: 100% H3: 100%
		APOC3 c.55+1G>A	1	7	0.00 (-0.05;0.05)	1.00	
		ANGPTL3	3	-	- 0.34 (-0.38;-0.31)	6e-206	H3: 100%
Triglycerides	343,992	ANGPTL4	1		- 0.65 (-0.74;-0.56)	1e-125	H4: 100%
		APUC3 APOC3 c 55+165A	2	*	- 0.58 (-0.62;-0.53)	<2e-308	H3: 100%
		APOUS C.SSTIGSA	3		- 0.39 (-0.44,-0.33) - 0.15 (-0.19:-0.12)	2e-57	H3: 100%
LDL cholesterol	343.621	ANGPTL4	1	<u> </u>	-0.02 (-0.09:0.06)	1.00	H1: 96%
		APOC3	2	<b>F</b>	- 0.10 (-0.14;-0.06)	6e-18	H3: 100%
		APOC3 c.55+1G>A	1		- 0.07 (-0.11;-0.03)	2e-07	
		ANGPTL3	3		- 0.02 (-0.03;-0.01)	4e-05	H3: 100%
HDL cholesterol	315,133	ANGPTL4	1	+	+ 0.24 (0.21;0.28)	7e-134	H4: 100%
		APOC3	2		+ 0.16 (0.14;0.17)	2e-238	H4: 100%
		APOC3 C.35+1G>A	1	-1 0 1	+ 0.17 (0.15,0.18)	38-200	
				Lipids (mmol/L) per s.d. lowered protein abundance (95% CI)			
Apolipoprotoin P	242 500	ANGPTL3	3	<b>_</b>	- 0.03 (-0.04;-0.03)	3e-36	H3: 100%
Apolipoprotein B	342,590	ANGPTL4	2	3	-0.02(-0.04,0.00)	10.038	H4: 00%
		APOC3 c.55+1G>A	1	<b>1</b>	-0.02(-0.03;-0.01)	7e-09	113. 100 /8
		ANGPTL3	3	÷ 1	- 0.05 (-0.05;-0.04)	1e-51	H3: 100%
Apolipoprotein A	1 313,387	ANGPTL4	1		+ 0.11 (0.09;0.14)	1e-55	H4: 100%
		APOC3	2	-	+ 0.07 (0.06;0.08)	7e-94	H3: 100%
		APOC3 c.55+1G>A	1	<b></b>	+ 0.10 (0.09;0.11)	3e-139	
				-0.3 0.0 0.3			
		ANGPTI 3	3		_0.09 (_2.13:1.95)	1.00	H1· 07%
Lipoprotein(a)	273.896	ANGPTL4	1	<u> </u>	0.86 (-4.06:5.77)	1.00	H1: 96%
		APOC3	2	4	-0.99 (-3.32;1.34)	1.00	H1: 95%
		APOC3 c.55+1G>A	1	+	-0.19 (-2.84;2.46)	1.00	
			Lie	-50 0 50			
		ANGPTL3	3		-0.02 (-0.25;0.22)	1.00	H1: 96%
Hemoglobin A1c	344,182	ANGPTL4	1		-0.47 (-1.03;0.09)	0.29	H1: 80%
		APOC3	2	t	0.06 (-0.21;0.33)	1.00	H1: 92%
		APOC3 c.55+1G>A	1		0.14 (-0.16;0.45)	1.00	
				-7 0 7 bA1c (mmol/mol) per s.d. lowered protein abundance (95% CI)			
Systelic blood		ANGPTL3	3	<b>+</b>	0.16 (-0.31;0.62)	1.00	H1: 99%
Systolic blood	757,601	ANGPTL4	1	-==	-1.17 (-2.35;0.01)	0.053	H1: 55%
pressure		APOC3	1		- 1.43 (-2.50;-0.36)	6e-04	H3: 100%
		APOC3 c.55+1G>A	0			1.00	114 40004
Diastolic blood	757 601	ANGPIL3	3		-0.03 (-0.30;0.23)	1.00	H1: 100%
pressure	757,001	ANGP1L4 APOC3	1	3	-0.50 (-1.17,0.17)	0.71 7e_04	H3: 100%
		APOC3 c.55+1G>A	0		- 0.01 (-1.40,-0.20)	70-04	110. 100 /0
			Blo	-10 0 10	CI)		
		ANGPTI 3	3			1.00	H1· 95%
Waist to hip-ratio	697.734	ANGPTL4	1		- 0.09 (-0.16:-0.01)	0.004	H4: 86%
and the mp state	,	APOC3	2	7	0.01 (-0.02;0.05)	1.00	H3: 98%
		APOC3 c.55+1G>A	1	÷-	0.02 (-0.02;0.06)	1.00	
Body fat		ANGPTL3	3	<u>↓</u>	-0.01 (-0.03;0.01)	1.00	H1: 99%
percentage	454,633	ANGPTL4	1	<b>-</b>	+ 0.07 (0.01;0.12)	0.008	H4: 78%
		APUC3 APOC3 c 55±10>4	1	Ť	0.03 (-0.03;0.08)	1.00	H3: 100%
		ANGPTL3	3	4	-0.02 (-0.05:0.00)	0.13	H1: 93%
Body mass index	806,834	ANGPTL4	1	+	0.01 (-0.06;0.09)	1.00	H1: 95%
	.,	APOC3	2	÷	0.00 (-0.04;0.03)	1.00	H3: 100%
		APOC3 c.55+1G>A	1	<del>_</del>	-0.01 (-0.05;0.03)	1.00	
				-1 0 1			
		1	Anthropo	netric measurement (s.d.) per s.d. lowered protein abundance	(95% CI)		
				Risk marker Risk marker			
				target protein lowering target protein lowering			

#### Cardiometabolic risk markers Exposure: Target protein abundance (ANGPTL3, ANGPTL4, APOC3 cis-pQTLs)

310

Figure 3. Results of MR analyses of cardiometabolic disease risk factors.

311 312 313 314 The results are presented as bar plots, showing the magnitude of the effect per s.d. lowered protein abundance. The red lines indicate the 95 % CI. The results from cis-pQTL MR of the estimated glomerular filtration rate (eGFR) by Cystatin C and plasma Creatinine, respectively, are given in Supplemental Figure 3.

## 315 Step 2

319

## 316 Drug-target MR of potential adverse effects

317 Genetic lowering of plasma protein levels of the target genes was not associated with any of the MRI

318 imaging endpoints (Figure 4A). 9, 3, 9, and 6 out of the 43 routine clinical laboratory tests showed

statistically significant associations by drug-target cis-pQTL MR of the ANGPTL3, ANGPTL4,

- 320 APOC3, and c.55+1G>A models, respectively (Figure 4B). The effect magnitudes were weak. For
- 321 example, genetically lowered ANGPTL3 and APOC3 levels were significantly associated with
- 322 increased platelet count. However, the effect was estimated to be  $4-5 \times 10^9$  cells/L (equalling 0.06-0.08
- 323 s.d.) per s.d. lowered plasma protein levels, which was minimal compared to the population mean value
- 324 of  $252 \times 10^9$  cells/L.
- 325 Given that safety concerns have arisen from preclinical models of ANGPTL4 deficiency, we conducted 326 targeted cis-pQTL MR analyses of ANGPTL4 on disease phenotypes that may be associated with 327 abdominal lymphadenopathy. The mechanism behind the fatal chylous lymphadenopathy observed in 328 mice was purportedly the loss of inhibition of LPL in macrophages, which caused them to take up excess 329 lipids, leading to massive inflammation in the mesenteric lymph system (14). Exposure to ANGPTL4 330 inactivation was instrumented using two different models: by the ANGPTL4 p.E40K coding variant, and 331 by the ANGPTL4 p.Cys80frameshift (fs) variant. ANGPTL4 p.Cys80fs is a high-confidence predicted 332 loss-of-function variant (gnomAD v.4.0.0). It is enriched in Finns compared to non-Finnish Europeans 333 (allele frequency: 0.63% vs. 0.05%). Cis-pOTL MR via the relatively common ANGPTL4 p.E40K 334 variant was conducted at five different phenotypes that may be related to lymphadenopathy and 335 malabsorptive states. Four had overlapping phenotype codes between the UK biobank and FinnGen and 336 were meta-analyzed using IVW meta-analysis. ANGPTL4 levels via p.E40K were not associated with 337 any of the five phenotypes (Figure 4C). However, since the confidence intervals were wide, we cannot 338 fully exclude an association of p.E40K within this interval. Genetically lowered plasma ANGPTL4 339 levels via the ANGPTL4 p.Cys80fs variant were not associated with any of the four FinnGen phenotypes 340 that may be related to lymphadenopathy and malabsorptive states (Figure 4C).

341 To investigate if there was any genetic evidence for unknown ANGPTL4-mediated side effects, we 342 performed cis-pQTL MR on 694 disease-related phenotypes in FinnGen and the UK Biobank via the ANGPTL4 p.E40K and p.Cys80fs variants. Using a phenome-wide significance threshold of  $P \leq \frac{0.05}{3\times 694}$ , 343 344 we found no evidence for increased risk of any endpoint via p.E40K- or p.Cys80fs-lowered ANGPTL4 345 levels (Figure 4D). Instead, we found phenome-wide evidence that p.E40K reduced the risk of four 346 CAD-related phenotypes, including myocardial infarction and one T2D-related phenotype, while also 347 being associated with a lowered probability of statin prescription, lipoprotein disorders, and 348 hypercholesterolemia (Figure 4D). Additionally, ANGPTL4 p.Cys80fs was associated with a decreased 349 risk of two T2D-related outcomes and a lowered probability of statin prescription and 350 hypercholesterolemia diagnosis (Figure 4D).

- 351 The phenome-wide MR results of lowered plasma ANGPTL4 levels were compared with ANGPTL3
- and APOC3 by cis-pQTL MR of the 694 FinnGen and UK Biobank endpoints using the ANGPTL3
- 353 c.\*52 \*60del and APOC3 c.55+1G>A. Genetically lowered plasma ANGPTL3 levels were associated
- 354 with a reduced risk of being prescribed statin medication, two lipid-related diagnosis codes but not any
- 355 other patient-related outcome (Supplemental Figure 4A). APOC3 c.55+1G>A was associated with a
- 356 reduced risk of statin prescription but not any other endpoint (Supplemental Figure 4B).



C. Lymphadenopathy

Exposure: ANGPTL4 protein abundance (ANGPTL4 cis-pQTLs)

Odds ratio per s.d. lowered protein abundance (95% CI)

Variant	Outcome	Events/Total				Odds ratio (95% CI)	P-value
ANGPTL4 p.E40K	Acute lymphadenitis	6,597 / 700,506		<u>i</u>		1.03 (0.74;1.44)	0.86
	Acute peritonitis	3,362 / 689,698				0.77 (0.46;1.29)	0.33
	Ascites (non malignant)	3,384 / 367,211				1.13 (0.66;1.93)	0.65
	Intestinal malabsorption	1,693 / 600,069	_			0.99 (0.50;1.97)	0.98
Noninfec	ctious disorders of the lymphatic system	2,809 / 680,456		<b>_</b>		1.18 (0.69;2.00)	0.55
ANGPTL4 p.Cys80fs	Acute lymphadenitis	1,615 / 325,625		<u> </u>		1.22 (0.96;1.55)	0.11
	Acute peritonitis	1,643 / 341,350		<del></del>		1.11 (0.87;1.41)	0.39
	Intestinal malabsorption	1,073 / 329,277		<del>`</del>		1.03 (0.77;1.38)	0.83
Noninfec	ctious disorders of the lymphatic system	798 / 295,812		<del>_</del>		1.01 (0.71;1.43)	0.96
			0.25 0.5	1	2 4		

#### D. PheWAS



357 358

Figure 4. Results of MR analysis of potential adverse effects.

359 A: Cis-pQTL MR results on the imaging outcomes. Bar plots and red lines indicate the effect and 95% CI:s. 'scWAT' indicates 360 subcutaneous white adipose tissue. 'vol.' indicates volume. B: Cis-pQTL MR of the clinical laboratory outcomes. The red bars 361 indicate the 95 % CI. The black dots indicate the effect point estimate. \* indicate P < 0.05. \*\* indicates P < 0.05 with a shared causal variant (H<sub>4</sub>). A list explaining the abbreviations is provided in the supplemental material (Table S1). Supplemental 363 Figure 5 shows the results on a 1-s.d. scale. C: Results of ANGPTL4 cis-pQTL MR of mesenteric lymphadenopathy and 364 malabsorption-related phenotypes. D: Volcano plot displaying the results of ANGPTL4 cis-pQTL phenome-wide MR scans on

365 694 outcomes in the FinnGen and UK Biobank meta-analysis (see **Table 2** and **Supplemental Table 1** for the reference and link to data, respectively). The *y*-axis solid straight lines indicate the phenome-wide significance threshold.

## **367** Step 3

## 368 Common variants in *ANGPTL3*, *ANGPTL4*, and *APOC3* share their metabolic fingerprint with 369 deleterious variants

- In line with a previous investigation (45), we found no significant association between ANGPTL3 inactivation via common variants and CAD. Previously, however, evidence was presented that deleterious variants in *ANGPTL3* are associated with a decreased risk of CAD (46, 47). As the common
- 373 variants adjacent to ANGPTL3 only modestly impacted plasma lipids, it could be argued that they do
- 374 not accurately reflect the effects of more profound *ANGPTL3* inactivation. Therefore, we examined
- 375 whether common variants adjacent to ANGPTL3, ANGPTL4, and APOC3 mimicked the effects (that is,
- 376 showed the same effect directionality) of deleterious variants.
- All common variants adjacent to *ANGPTL3*, *ANGPTL4*, and *APOC3* were highly concordant with deleterious variants within the same gene (**Figure 5A-C**). One hundred sixty-seven metabolite associations near *ANGPTL3* showed a high concordance metric ( $R^2$ ) of 84% between the common variants and deleterious models. *ANGPTL4* common variants were also highly concordant with *ANGPTL4* deleterious variants, having an  $R^2$  of 86%. *APOC3* showed a concordance metric  $R^2$  of 87%. These results demonstrate that the common genetic variations adjacent to *ANGPTL3*, *ANGPTL4*, and
- 383 *APOC3* would be valid genetic instruments reflecting a modest "knock-down" of each respective gene.384

# Comparative drug-target MR of LPL and endothelial lipase (EL) reveals that in order to achieve CAD benefits, ANGPTL3 inhibition should primarily target LPL rather than EL

- 387 ANGPTL3 targets both EL and LPL and may thus influence CAD via two independent pathways (48).
- 388 To compare the effects of these two target enzymes, we analyzed the effects of genetically instrumented
- 389 EL and LPL activity on CAD by performing functional-variant limited MR of the *LIPG* (encoding EL)
- 390 and LPL genes. We used the preferred enzyme substrate as the exposure, as EL prefers lipoprotein
- 391 phospholipids, whereas LPL primarily hydrolyzes lipoprotein TGs (49). We detected two functional
- 392 LPL variants and four functional LIPG variants with small to large effects on plasma TG/lipoprotein
- 393 phospholipids (range: 0.02 0.6 s.d. per allele).
- 394 MR analysis of LPL and LIPG found opposing significant associations with CAD for LPL (IVW meta-
- analysis: OR: 0.74,  $P=1\times10^{-4}$ ) and EL (IVW meta-analysis OR: 1.38,  $P=5\times10^{-7}$ ) (Figure 5D). These
- 396 findings suggest that increased activity of LPL protects against the development of atherosclerosis,
- 397 whereas heightened activity of EL may contribute to the acceleration of atherosclerosis. The contrasting
- 398 impact of genetic EL and LPL activity on CAD risk suggests that for ANGPTL3 inactivation to lower
- 399 CAD risk, it may need to have a greater impact on LPL activity compared to EL activity.



Common variant model effect on lipid metabolite per s.d. TG lowering

#### Coronary artery disease MR of LPL and LIPG functional variants

LIPG (outcome: CAD, exposure: plasma lipoprotein phospholipids)

D.

•			•	• • •						,
Variant	Consequence	Events / Total	Freq.	Method		Odds ratio [95% CI] (P-value)	PL (s.d.)	TG (s.d.)	LDL-C (s.d.)	HDL-C (s.d.)
18:49562285:T>G	5 prime UTR premature start codon gai	180,249 / n 1,162,820	0.3206 (0.98)	Wald ratio		1.67 [1.09;2.57] (P=0.02)	0.02 [0.02;0.03]	-	-	0.03 [0.03;0.04]
18:49575468:G>A	Missense [p.Arg224His] SIFT: deleterious	53,953 / 544,132	0.0005 (0.7)	Wald ratio		0.77 [0.25;2.39] (P=0.65)	0.37 [0.15;0.59]	-	-	0.38 [0.27;0.48]
18:49583585:A>G	Missense [p.Asn396Ser] PolyPhen: probably damagi	170,178 / ing 1,133,320	0.0123 (0.98)	Wald ratio	-	1.34 [1.15;1.56] (P=2e-04)	0.30 [0.26;0.34]	0.04 [0.02;0.06]	0.07 [0.05;0.09]	0.29 [0.27;0.31]
18:49586795:C>T	Missense [p.Arg476Trp] SIFT: deleterious	123,638 / 933,548	0.0023 (0.96)	Wald ratio	¦	1.50 [1.13;1.98] (P=0.004)	0.47 [0.38;0.56]	0.07 [0.02;0.11]	0.11 [0.06;0.15]	0.40 [0.35;0.44]
	Cor	mbined (Heterog	eneity: Q=	2.28; P=0.52)	•	1.38 [1.22;1.57] (P=5e-07)				

0.25 0.5 1 2 4

LPL (outcome: CAD, exposure: plasma TG)

Variant	Consequence Events / Tota	l Freq.	Method		Odds ratio [95% CI] TG (P-value) (s.d.)	HDL-C (s.d.)
8:19954222:G>A	Missense [p.Gly215Glu] 65,057 / PolyPhen: probably damaging 568,082	0.0006 (1)	Wald ratio		0.48 [0.30;0.77] 0.60 (P=0.002) [ 0.41; 0.80]	0.80 [-0.90;-0.71]
8:19962213:C>G	Stop gained [p.Ser474Ter] 177,063 / paradox. gain-of-function 1,157,050	0.0974 (1)	Wald ratio	-	0.75 [0.69;0.82] -0.19 (P=2e-11) [-0.21;-0.18]	0.17 [ 0.17; 0.18]
	Combined (Hetero	geneity: Q=3.3	7; P=0.066)	•	0.74 [0.64;0.86] (P=1e-04)	
				0.25 0.5 1 2 4		

Coronary artery disease odds ratio per s.d. lowered triglycerides (95% CI)

#### E. Coronary artery disease MR of ANGPTL3 and ANGPTL4 functional variants

ANGPTL3 (outcome	e: CAD	, exposure:	plasma TG	)								Variant effect	on protein abu	ndance / plasm	a lipids [95% C	4]
Variant	Consequ	Jence I	Events / Total	Freq. (info)	Method						Odds ratio [95% Cl (P-value)	] Protein (s.d.)	TG (s.d.)	LDL-C (s.d.)	HDL-C (s.d.)	
1:62598067:T>C	Splice reg Splice	gion [c.495+6T>C] Al: donor loss	] 80,569 / 895,497	0.0019 (0.93)	Wald ratio		_				1.00 [0.68;1.46] (P=0.99)	-1.50 [-1.69;-1.31]	-0.49 [-0.56;-0.42]	-0.25 [-0.32;-0.18]	-0.11 [-0.18;-0.04]	
1:62601804:G>T	Missens SIFT	e [p.Gly253Cys] : deleterious	63,005 / 562,146	0.0007 (0.87)	Wald ratio			; ; = ;			1.21 [0.52;2.83] (P=0.66)	-1.56 [-1.98;-1.14]	-0.47 [-0.63;-0.32]	-0.22 [-0.38;-0.06]	-	
1:62604032:G>A	Missens SIFT	e [p.Arg332GIn] : deleterious	38,405 / 492,981	0.0022 (0.61)	Wald ratio			 			0.96 [0.66;1.40] (P=0.83)	-2.53 [-3.16;-1.90]	-0.62 [-0.94;-0.30]	-	-	
1:62604866:AGTTAATGTG	3j à>A [c.'	prime UTR *52_*60del]	159,190 / 1,110,890	0.3402 (0.99)	Wald ratio		-	- -			0.93 [0.81;1.06] (P=0.28)	-0.28 [-0.30;-0.27]	-0.08 [-0.08;-0.07]	-0.04 [-0.04;-0.03]	-0.01 [-0.02;-0.01]	
		Com	bined (Heterog	eneity: Q=	0.49; P=0.92)		-				0.94 [0.83;1.06] (P=0.34)					
						0.25	0.5	i 1	2 4	1						
ANGPTL4 (outcome	e: CAD,	exposure:	plasma TG	) Cor	onary artery dis	sease od	lds ratio p	oer s.o	l. lowere	ed trig	glycerides (95% (	CI)				
19:8364439:G>A	Missen SIFT	se [p.Glu40Lys] : deleterious	164,838 / 1,122,180	0.0224 (0.86)	Wald ratio			+	1		0.46 [0.39;0.54] (P=4e-21)	-0.35 [-0.39;-0.30]	-0.23 [-0.24;-0.21]	-	0.20 [0.19;0.22]	
19:8371489:C>T	Missens SIFT	e [p.Arg336Cys] : deleterious	132,683 / 975,311	0.0028 (0.98)	Wald ratio	-					0.16 [0.04;0.62] (P=0.009)	-0.77 [-0.89;-0.65]	-0.08 [-0.12;-0.04]	-	0.09 [0.05;0.13]	
		0.0	mbined (Listers		0.0. D 0.10)			-	1		0.45 [0.36;0.58]					

<sup>0.05 0.25 1 4</sup> 

Coronary artery disease odds ratio per s.d. lowered triglycerides (95% CI)

(P=2e-10)

#### 400

#### 401 Figure 5. Results of validation analyses.

The concordance between the effect directionality of CVs and PTVs is displayed using scatter plots with a regression line. **A**: Comparison of the effect directionality between *ANGPTL3* CVs and PTVs. **B**: *ANGPTL4* CVs vs. PTVs. **C**: *APOC3* CVs vs. PTVs. 'R<sup>2</sup>' represents the coefficient of determination. 'Int.' indicates the regression line intercept. The color of the scattered dots indicates the lipid class of the NMR parameter. The collapsing model estimates were scaled by their 1-s.d. effect on plasma TGs to improve interpretability. **D**: Forest plots and tables showing the results of the CAD MR analysis focusing on functional variants in *LPL* and *LIPG*. Genetic association summary statistics of *LIPG* with the exposure were extracted from the UK

biobank NMR study of 115,078 individuals retrieved from (36). LPL variant associations were retrieved from the same data set.

409 410 411 412 CAD data was from the Aragam et al. meta-analysis (30). E: Forest plots and tables showing the results of the CAD MR analysis that limited the selection of genetic instruments to functional variants in ANGPTL3 and ANGPTL4. "Freq." represents the alternative allele frequency. "info" represents the imputation quality metric derived from the outcome GWAS. Variant effects on plasma lipids were retrieved from (23). The ANGPTL4 p.Glu40Lys (p.E40K) estimates differ slightly from Figure 2 because a 413 414 slightly different estimator and UK Biobank subcohort were used to measure the association between the functional variants and plasma TGs.

## 415 Step 4

423

## 416 Deleterious variants in ANGPTL3, ANGPTL4, and APOC3, and the risk of CAD

- 417 Two previous studies found that deleterious variants in ANGPTL3 protected against CAD (3, 46). In an
- 418 effort to reproduce these findings, we performed a sensitivity MR analysis of CAD and limited the
- 419 selection of genetic instruments to functional variants. Functional annotations were detected for four
- 420 ANGPTL3, two ANGPTL4, and one APOC3 variant. The detected APOC3 variant was the c.55+1G>A
- 421 splice donor loss variant, which was already reported in Figures 2-4. The other variants associated with
- 422 lowered protein levels and triglycerides, with effect sizes ranging from profound to modest (protein
- 424 and together using random-effects IVW meta-analysis. *Cis*-pOTL MR of the *ANGPTL3* variants

range: -2.53--0.28; TG range -0.28--0.62) (Figure 5E) (22). The variants were analyzed individually

- 425 indicated that ANGPTL3 protein levels were not significantly associated with CAD, individually or
- 426 together (meta-analysis IVW OR per s.d. TG: 0.94, P=0.34) (Figure 5E). By contrast, reduced
- 427 ANGPTL4 protein levels were associated with a decreased risk of CAD (meta-analysis IVW OR: 0.45
- 428 per s.d. TG,  $P=2\times 10^{-10}$ ) (Figure 5E).
- 429 Considering the beneficial effects of ANGPTL3, ANGPTL4, and APOC3 on plasma lipids, it was
  430 expected that genetic inactivation of these proteins would confer protection against CAD. However, the
  431 ANGPTL3 MR analyses focusing on common variants and MR of functional variants (identified
- 432 through DNA microarrays) did not support this hypothesis. Therefore, we pursued a meta-analysis of
- 433 DNA sequencing-based studies that studied the effect of ANGPTL3, ANGPTL4, and APOC3 deleterious
- 434 variants on CAD. The rationale for excluding DNA microarray and exome bead chip-based studies was
- 435 the potential risk of introducing measurement error for rare variants (50, 51), leading to bias towards the
- 436 null hypothesis. DNA-sequencing-based substudies from previous papers (3, 46, 52, 53), were extracted
- 437 and analyzed together with genetic association analyses conducted in the UK Biobank. Loss-of-function
- 438 variant genetic association effect sizes typically range from -1 to -3 s.d. for their affected protein (22).
- 439 The carrier status of deleterious variants was associated with substantial decreases in protein levels for
- 440 both ANGPTL3 (-1.29 s.d. protein,  $P=9\times10^{-32}$ ) and ANGPTL4 (-1.33 s.d. protein,  $P=1.4\times10^{-43}$ ). APOC3
- 441 protein levels were not measured in the UK Biobank. However, APOC3 deleterious variants were
- 442 associated with a significant reduction in TG (-0.68 mmol/L TG,  $P=1\times10^{-82}$ ).
- 443 The results of the meta-analysis are presented in Figure 6. The presence of ANGPTL3 deleterious
- 444 variants was associated with reduced CAD risk (meta-analysis IVW OR: 0.41 per TG,  $P=3\times10^{-5}$ ).
- 445 *ANGPTL4* deleterious variant carrier status, excluding p.E40K, was also associated with a reduced risk
- 446 of CAD (meta-analysis IVW OR: 0.32 per TG, P=0.016), as was APOC3 deleterious variant carriers
- 447 status (meta-analysis IVW OR: 0.70 per TG, P=0.005). The key finding was the robust association of
- 448 *ANGPTL3* deleterious carrier status with a reduced risk of CAD. This association was not detected with
- the other approaches and implies that ANGPTL3 lowering might offer atheroprotective benefits similar
- 450 to ANGPTL4 or APOC3 lowering.

ANGPTL3		diseas	e cases	<sup>y</sup> Co	ontrol	per mmol/L TG	per allele	
Study	Ancestry	Carriers	Non- Carriers	Carriers	Non- <sup>S</sup> Carriers	Odds ratio [95% Cl (P-value)	Odds ratio [95% Cl (P-value)	] TG reduction (mmol/L)
Biolmage study	Eur.	0	54	2	349	€ 2.08 [0.00; 17783] (P=1.00)	1.28 [0.06; 27.2] (P=1.00)	-
Registre Gironi del COR	Eur.	2	380	1	401	9.14 [0.01; 11396] (P=1.00)	2.11 [0.19; 23.4] (P=1.00)	-
South German Myocardial Infarctior study	Eur.	0	400	1	398	0.04 [0.00; 772] (P=0.52)	0.33 [0.01; 9.43] (P=0.52)	-
Jackson Heart Study	Eur.	1	133	11	2,031	2.65 [0.01; 1147] (P=1.00)	1.39 [0.18; 10.8] (P=1.00)	
North German Myocardial Infarction study	Eur.	4	853	2	869	8.27 [0.05; 1284] (P=1.00)	2.04 [0.37; 11.2] (P=1.00)	-
Ottawa Heart Study	Eur.	0	956	2	964	0.01 [0.00; 65.6] (P=0.30)	0.20 [0.01; 4.10] (P=0.30)	
Precocious Coronary Artery Disease study	Eur.	4	909	3	901	2.28 [0.03; 198] (P=1.00)	1.32 [0.29; 5.96] (P=1.00)	
Atherosclerosis Risk in Communitie	s Eur.	0	773	18	6,464	0.01 [0.00; 83.6] (P=0.33)	0.23 [0.01; 4.45] (P=0.33)	
talian Atherosclerosis Thrombosis and Vascular Biology	Eur.	6	1,763	5	1,694	=→ 1.51 [0.04; 51.6] (P=1.00)	1.15 [0.35; 3.78] (P=1.00)	-
Exome Sequencing Project Early-Onset Myocardial Infarction	Eur.	3	567	9	1,389	0.56 [0.01; 27.0] (P=0.77)	0.82 [0.22; 3.04] (P=0.77)	
eicester Myocardial Infarction	Eur.	2	1,218	6	1,090	0.03 [0.00; 3.26] (P=0.14)	0.30 [0.06; 1.49] (P=0.14)	
aeisinger Health System DiscovEHR)	Eur.	43	13,059	183	40,247	0.27 [0.11; 0.67] (P=0.005)	0.59 [0.41; 0.85] (P=0.005)	-0.4 [CI: -0.49; -0.32
Copenhagen General Population	Eur.	10	11,162	131	96,585	0.25 [0.03; 1.87] (P=0.18)	0.63 [0.32; 1.24] (P=0.18)	
Iniversity of Pennsylvania ledicine Biobank	Eur.	8	3,983	20	3,538	0.09 [0.01; 1.45] (P=0.09)	0.45 [0.18; 1.13] (P=0.09)	
Ouke Catheterization Genetics ohort	Eur.	12	4,507	3	1,466	2.33 [0.05; 110] (P=1.00)	1.33 [0.36; 4.88] (P=1.00)	
Inited Kingdom Biobank	Eur.	241 4	41,904	928	136,761	0.55 [0.33; 0.93] (P=0.026)	0.84 [0.72; 0.98] (P=0.026)	-0.30 [Cl: -0.36; -0.24
Vooled estimate Heterogeneity: Q=6.62; P=0.97)		336 8	82,621	1,325	295,147	0.41 [0.27; 0.63] (P=3e-05)	0.79 [0.69; 0.90] (P=5e-04)	-0.34 [Cl: -0.39; -0.29]
						2 4 10		-
ANGPTL4 (excluding	ANGF	PTL4 p	.E40K)	)	Coronar	mmol/L lowered triglycerides (95% CI)		
Geisinger Health System DiscovEHR)	Eur.	13	10,539	58	29,165	0.05 [0.00; 0.95] (P=0.046)	0.56 [0.32; 0.99] (P=0.046)	-0.19 [Cl: -0.35; -0.03]
Jnited Kingdom Biobank	Eur.	161 4	41,984	630	137,059	0.39 [0.15; 1.03] (P=0.059)	0.83 [0.69; 1.01] (P=0.059)	-0.20 [Cl: -0.27; -0.13
Pooled estimate Heterogeneity: Q=1.72; P=0.19)		174	52,523	688	166,224	0.32 [0.13; 0.81] (P=0.016)	0.80 [0.67; 0.96] (P=0.015)	-0.20 [Cl: -0.26; -0.13
APOC3					Coronar	2 4 10		
Conenhagen City Heart Study	Fur	9	2 808	32	7 484	0.47 [0.18; 1.25]	0.60 [0.31; 1.16]	
,	Eur.	194 4	41.951	718	136.971	(P=0.13) 0.72 [0.56; 0.93]	(P=0.13) 0.80 [0.67; 0.95]	-0.68
Inited Kingdom Biobank	EUC.		,001			(P=0.012)	(P=0.012)	[CI: -0.75; -0.61
United Kingdom Biobank Pooled estimate	Eur.	203	14 750	750	144 455	0.70 [0.54; 0.90]	0.78 [0.66; 0.93]	-0.68

#### Meta-analysis of Coronary Artery Disease vs. Deleterious Variants in DNA Sequencing Studies

## 451

#### Figure 6. Meta-analysis of deleterious variants in ANGPTL3, ANGPTL4, and APOC3, and the risk of CAD.

452 453 454 455 456 Forest plots and tables indicating the effect on CAD per mmol/L TG, and per allele. The deleterious variant effect estimates for each substudy were retrieved from (3, 23, 46, 52, 53). The case definition used in the Copenhagen City Heart Study was not exclusively restricted to CAD. 21% of the ischemic vascular disease cases were diagnosed with atherosclerotic cerebrovascular disease, rather than CAD (with CAD encompassing 79 % of the cases) (53). 'Eur.' denotes European ancestry.

## 457 **DISCUSSION**

458 We find that targeted inactivation and associated lowering of plasma APOC3 levels is predicted to 459 decrease plasma TG and LDL and raise HDL levels. Targeted lowering of plasma ANGPTL3 is expected 460 to reduce plasma TG, LDL, and HDL levels, while lowering of plasma ANGPTL4 is predicted to 461 decrease plasma TG and increase HDL levels. Based on these findings, it is expected that genetic 462 inactivation of APOC3, ANGPTL3, and ANGPTL4 levels is associated with protection against CAD. 463 Through MR and a meta-analysis of rare variant genetic association studies, we confirmed that targeted 464 inactivation and lowering of ANGPTL3, ANGPTL4, and APOC3 is associated with a lowered risk of 465 CAD. In addition, lifetime genetic lowering of ANGPTL4 was observed to reduce the risk of T2D, 466 indicating that ANGPTL4 inhibition might provide additional benefits to patients with T2D and

467 dyslipidemia.

468 The inactivation of ANGPTL4 in mice and monkeys was shown to lead to mesenteric lymphadenopathy 469 and other severe complications. Naturally, these observations raised serious concerns about the safety 470 of pharmacological targeting of ANGPTL4. Here, we did not find an association between genetic 471 ANGPTL4 inactivation and several disease codes related to lymphatic disorders. While these data do 472 not entirely exclude any harmful effects of ANGPTL4 inactivation, they do mitigate safety concerns 473 about the impact of whole-body inactivation of ANGPTL4 in humans. Recently, it was shown that 474 silencing of ANGPTL4 in the liver and adipose tissue using ASO markedly reduces plasma TG levels 475 in mice yet does not lead to mesenteric lymphadenopathy or other complications (16). These data 476 suggest that liver- and adipose tissue-specific inactivation of ANGPTL4 may confer similar 477 cardiovascular benefits as whole-body ANGPTL4 inactivation without any particular safety risks.

The association of ANGPTL4 with T2D was distinct from the other proteins that inhibit LPL. In preclinical studies, mice overexpressing LPL in muscle were more insulin resistant, while mice lacking LPL in muscle were more insulin sensitive. In contrast, mice overexpressing LPL in adipocytes were more insulin sensitive (54, 55). The protective effect of enhanced LPL action in adipose tissue may be related to increased lipid partitioning into the adipose tissue and reduced ectopic fat. While ANGPTL3, ANGPTL4, and APOC3 all act through LPL, only ANGPTL4 acts exclusively via LPL, which may explain why only genetic variation in ANGPTL4 is associated with T2D risk.

485 Previous studies reported conflicting findings regarding the association between ANGPTL3 and CAD.

486 Dewey et al. (3), and Stitziel et al. (46) found that rare deleterious ANGPTL3 variants were associated

487 with decreased odds of ASCVD, whereas MR studies of common ANGPTL3-lowering variants reported

- 488 negative findings (45). By meta-analysis of deleterious variant genetic association studies, we found
- 489 clear, statistically robust evidence that lifetime genetic inactivation of ANGPTL3 confers protection
- 490 against CAD. These findings align with recent case reports indicating that ANGPTL3 lowering with
- 491 Evinacumab protects against atherosclerosis progression in HoFH patients (11, 12). A recent and similar
- 492 UK Biobank study examining the impact of protein-truncating ANGPTL3 variants on CAD found no
- 493 association (56). Compared to their analysis, key differences were a broader case definition, a stricter

definition of controls, the inclusion of deleterious missense variants, and the meta-analysis, which
incorporated evidence from previous studies. These methodological differences strengthened statistical
power in our study, making a false negative finding less probable.

497 The discrepancy between the deleterious and common ANGPTL3 variants in terms of their association 498 with CAD could be due to a range of different factors. One possible explanation is the pleiotropic effects 499 of ANGPTL3. Besides inhibiting LPL, ANGPTL3 inhibits endothelial lipase (EL) (57). In a recent 500 paper, we showed that the LPL-independent effects of ANGPTL3 inactivation on plasma metabolic 501 parameters showed a striking inverse resemblance with EL inactivation, suggesting that ANGPTL3 502 modulates plasma lipid levels by inhibiting LPL and EL (41). Here, using MR, we compared the effects 503 of genetically instrumented EL and LPL activity on CAD. Whereas increased LPL activity reduced the 504 odds of CAD, increased EL activity increased the odds of CAD. The observed link between EL and 505 CAD is consistent with previous human genetic studies showing the possible harmful effects of a 506 genetically predicted increase in EL activity (58, 59). This suggests that ANGPTL3's interaction with 507 EL might counteract its cardiovascular benefits achieved through LPL inhibition under certain 508 physiological conditions. While our research demonstrated metabolic concordance between ANGPTL3 509 common variants and deleterious variants, it remains possible that more profound ANGPTL3 510 inactivation by deleterious variants could tip the balance in favor of LPL inhibition over EL. This shift 511 could potentially enhance the anti-atherosclerotic benefits of ANGPTL3 lowering.

512 Interestingly, the association of ANGPTL3 inactivation with CAD was only present for rare deleterious 513 variants when the carrier status was determined by DNA sequencing. This exposes the limitations of 514 drug-target MR studies using DNA micro-array-based GWAS. When rare variants are incorrectly 515 imputed, this typically introduces a one-sided loss of information that biases toward the null hypothesis, 516 leading to falsely negative findings (51). Even though the imputation quality score (e.g., 'INFO') reports 517 an imputation quality metric, this metric does not really measure the true imputation accuracy (60). The 518 imputation accuracy can only truly be determined if variant carrier status is called by genotyping (e.g., 519 via DNA sequencing). However, studying rare variants in genetic association studies is not without 520 drawbacks. An important limitation of rare variants is statistical imprecision simply due to their rarity 521 (61). Rare variants also often emerged relatively recently and consequently are more susceptible to 522 confounding by enrichment in specific geographical regions, families, or socioeconomic strata (62). 523 Even if appropriate model adjustments are applied, subtle differences in population structure could cause 524 a small number of extra alleles to be present in the control (or case) group. This can lead to biased 525 estimates when the rare alternative allele is present in ten, or hundred individuals in total, which is often 526 the case for rare variant studies even when the total sample size is above hundreds of thousands. Overall, 527 our findings underscore the importance of combining evidence from rare deleterious and benign 528 common variants in genetic association studies of complex disease phenotypes. 529 The complexity of the APOA1-APOA5-APOC3 locus and the potential confounding due to LD poses

530 significant challenges in separating the genetic association signals. The use of APOC3 c.55+1G>A as a

531 genetic instrument was justified because of its independence from common variants within this region, 532 making it ideal for studying APOC3 inactivation specifically. On the other hand, the analyses of APOC3 533 inactivation that did not include the c.55+1G>A variant should be interpreted with caution. Compared 534 to clinical trials, MR analysis can exaggerate the magnitude of the effect of inactivating a gene/protein 535 (63). Cis-pQTL MR utilizing protein-coding variants warrants extra carefulness due to the possibility of 536 epitope-binding artifacts, which may complicate the precise interpretation of effect sizes. The p.E40K 537 coding variant was the only variant qualifying as a *cis*-pQTL in the *ANGPTL4* region in the Step 1-2 538 analyses. While our validation analyses suggested this specific association was not attributable to 539 epitope-binding artifacts, we still advise caution when extrapolating effect sizes from the analyses. 540 Additionally, MR and other genetic association studies estimate lifelong exposure to changed gene 541 function, while drug trials typically last 2-5 years in late adulthood. If the treatment effect 542 multiplicatively interacts with time, MR may exaggerate it. This constraint should be considered when 543 translating MR findings to predict the results of clinical trials. For ANGPTL4, Dewey et al. (52), found 544 that the TG levels of p.E40K homozygotes were reduced by 0.58 mmol/L (0.92 mmol/L for p.E40K 545 homozygotes vs. 1.49 mmol/L in non-carriers; relative change -39%) in a normotriglyceridemic 546 population. When translating these findings (TG reduction of 0.58 mmol/L) onto the effect size on CAD 547 found in this study, one would expect that lifetime ANGPTL4 inactivation-in a population of 548 normotriglyceridemic individuals—results in a risk reduction corresponding to a CAD odds ratio of 0.61 549 (95% CI: 0.52–0.72).

550 In conclusion, our genetic analysis predicts that in a broader dyslipidemic patient population, therapies

551 aimed at decreasing plasma ANGPTL3, ANGPTL4, or APOC3 levels will be effective in preventing

552 CAD without raising specific safety concerns. In addition, therapies aimed at reducing plasma levels of

553 ANGPTL4 may provide additional benefits to patients with dyslipidemia and T2D.

## 554 ETHICAL REVIEW

- 555 This study analyzed scientific data that is available to the public, as detailed in Table 1 and
- 556 Supplemental Table 1, where references to the specific datasets can be found. Analyses using
- 557 individual-level access to the UK Biobank Resource were conducted under Application Number
- 558 #148828. The Erasmus Rucphen Family study was approved by the medical ethics board of the Erasmus
- 559 MC Rotterdam, the Netherlands (64). All studies complied with the ethical standards outlined in the
- 560 Helsinki Declaration.

## 561 ACKNOWLEDGEMENTS

- 562 We would like to thank Prof. Cornelia van Duijn and Prof. Ko Willems van Dijk for providing access
- 563 to samples from the Erasmus Rucphen Family study. We would like to thank the participants and
- 564 researchers of the CARDIoGRAMplusC4D, CKDGen, deCODE, DIAGRAM, EPIC-CVD, FinnGen,
- 565 GIGASTROKE, GLGC, and UK biobank studies, as well as the other non-consortium studies.

## 566 FUNDING

567 This research received no specific grants from public or non-profit funding agencies.

## 568 CONFLICT OF INTEREST

- 569 F.L. is a part-time employee of Lipigon Pharmaceuticals AB. S.K.N. is the chief executive officer of
- 570 Lipigon. S.K. is a paid consultant for Lipigon.

## 571 DATA AVAILABILITY STATEMENT

572 Database identifiers and links to the public data sets are provided in Supplemental Table 1. Access to 573 UK Biobank data is limited to authorized researchers who comply with data use policies to safeguard 574 participant confidentiality. Interested researchers must apply to UK Biobank, adhering to an application 575 process that ensures ethical and legal compliance in data handling. UK Biobank data set identifiers used 576 for the analyses under Application Number #148828 are provided in the Supplemental Methods. The 577 data from the Erasmus Rucphen Family study (ERF) cannot be shared publicly due to data protection 578 laws. Access to this data is restricted to ensure participant confidentiality, aligning with legal and ethical 579 obligations. Any request for access to the data for legitimate scientific purposes can be directed to the 580 principal investigators of the ERF study, subject to a rigorous review process ensuring that all legal and 581 ethical standards are met. The analyses in this manuscript were performed using the R programming 582 language (v.4.2.1) with the packages coloc, cowplot, data.table, ggplot2, ggthemes, mungegwas, 583 phewas, twosamplemr, wesanderson, writexl, and the Python programming language (v.3.8.16) using 584 the packages numpy, pandas, and scipy. The LD matrix estimates were calculated using PLINK 585 (v1.90b6.24).

## 586 **REFERENCES**

587 588 590 591 592 593 595 595 596 597 598 599 Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. 1. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401-12. Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of Angiopoietin-2. Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. Circulation. 2019;140(6):470-86. Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and 3 Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211-21. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, et al. ANGPTL3 Inhibition in Homozygous 4. Familial Hypercholesterolemia. N Engl J Med. 2017;377(3):296-7. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for 5. Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711-20. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in Patients 6. 600 601 with Refractory Hypercholesterolemia. N Engl J Med. 2020;383(24):2307-19. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, 7. 602 603 an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 604 2020;41(40):3936-45. 6Ŏ5 Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and Metabolic Effects of 8. 606 607 ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017;377(3):222-32. Watts GF, Schwabe C, Scott R, Gladding P, Sullivan D, Baker J, et al. Abstract 15751: 9. 608 Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like 609 Protein 3, in Patients With Hypercholesterolemia. Circulation. 2020;142(Suppl\_3):A15751-A. 610 611 Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of Vupanorsen on 10. Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: 612 613 614 615 TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377-86. Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked 11. plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13-7. Khoury E, Lauzière A, Raal FJ, Mancini J, Gaudet D. Atherosclerotic plaque regression in homozygous 12. 616 familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-<u>6</u>17 independent mechanisms. Eur Heart J Case Rep. 2023;7(1):ytad029. 618 619 Desai U, Lee EC, Chung K, Gao C, Gay J, Key B, et al. Lipid-lowering effects of anti-angiopoietin-like 4 13. antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A.  $620 \\ 621 \\ 622 \\ 623 \\ 624 \\ 625 \\ 626 \\ 627 \\ 628 \\ 629 \\ 630 \\ 631 \\ 632 \\ 633$ 2007;104(28):11766-71. Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, et al. Angptl4 14. protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12(6):580-92. Oteng AB, Bhattacharya A, Brodesser S, Qi L, Tan NS, Kersten S. Feeding Angptl4-/- mice trans fat 15. promotes foam cell formation in mesenteric lymph nodes without leading to ascites. J Lipid Res. 2017;58(6):1100-13. Deng M, Kutrolli E, Sadewasser A, Michel S, Joibari MM, Jaschinski F, et al. ANGPTL4 silencing via 16. antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy. J Lipid Res. 2022;63(7):100237. Davies BSJ. Can targeting ANGPTL proteins improve glucose tolerance? Diabetologia. 17 2018;61(6):1277-81. 18. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 634 635 2016;35(11):1880-906. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug 19. 636 637 638 639 640 target validation using Mendelian randomisation. Nat Commun. 2020;11(1):3255. 20. Timpson NJ, Walter K, Min JL, Tachmazidou I, Malerba G, Shin SY, et al. A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans. Nat Commun. 2014;5:4871. 21. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Largescale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712-21. 641 642 Dhindsa RS, Burren OS, Sun BB, Prins BP, Matelska D, Wheeler E, et al. Rare variant associations with 22. plasma protein levels in the UK Biobank. Nature. 2023;622(7982):339-47. 643 644 645 Wang Q, Dhindsa RS, Carss K, Harper AR, Nag A, Tachmazidou I, et al. Rare variant contribution to 23. human disease in 281,104 UK Biobank exomes. Nature. 2021;597(7877):527-32. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic 24. 646 insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508-18. 647 648 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access 25. resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 649 2015;12(3):e1001779. 650 651 652 653 654 Slatkin M. Linkage disequilibrium--understanding the evolutionary past and mapping the medical 26. future. Nat Rev Genet. 2008;9(6):477-85. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from Mendelian 27. randomization and colocalization: Review and comparison of approaches. Am J Hum Genet. 2022;109(5):767-82.

655 656 657 658 659 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383. Abraham W. The Fitting of Straight Lines if Both Variables are Subject to Error. The Annals of 29. Mathematical Statistics. 1940;11(3):284-300. 660 Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic 30. 661 characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 662 2022;54(12):1803-15. ĕ63 Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with 31. 664 kidney function from analyses of a million individuals. Nat Genet. 2019;51(6):957-72. 665 32. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke genetics informs drug 666 discovery and risk prediction across ancestries. Nature, 2022;611(7934):115-23. 667 668 Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic health record-based 33. genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. 669 Cell Rep Med. 2021;2(11):100437. 670 671 672 673 Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, et al. Fine-mapping type 2 34. diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50(11):1505-13. Nag A, Dhindsa RS, Middleton L, Jiang X, Vitsios D, Wigmore E, et al. Effects of protein-coding variants 35. 674 675 676 677 678 679 680 681 682 683 684 685 on blood metabolite measurements and clinical biomarkers in the UK Biobank. Am J Hum Genet. 2023;110(3):487-98. 36. Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv. 2020:2020.08.10.244293. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 37. 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50(10):1412-25. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-38. wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet. 2019;28(1):166-74. Stanzick KJ, Li Y, Schlosser P, Gorski M, Wuttke M, Thomas LF, et al. Discovery and prioritization of 39. variants and genes for kidney function in >1.2 million individuals. Nat Commun. 2021;12(1):4350. Liu Y, Basty N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N, et al. Genetic architecture of 11 organ 40. 686 687 688 689 traits derived from abdominal MRI using deep learning. Elife. 2021;10. Landfors F, Chorell E, Kersten S. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the 41. ANGPTL3-ANGPTL8 Complex and ANGPTL4. J Lipid Res. 2023;64(1):100313. Wang Q, Oliver-Williams C, Raitakari OT, Viikari J, Lehtimaki T, Kahonen M, et al. Metabolic profiling of 42. 690 691 692 angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. Eur Heart J. 2021;42(12):1160-9. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect 43. 693 694 695 696 Predictor. Genome Biol. 2016;17(1):122. 44. Yin W, Romeo S, Chang S, Grishin NV, Hobbs HH, Cohen JC. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem. 2009;284(19):13213-22. 45. Richardson TG, Leyden GM, Wang Q, Bell JA, Elsworth B, Davey Smith G, et al. Characterising 697 698 699 700 701 702 703 metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. PLoS Biol. 2022;20(2):e3001547. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, et al. ANGPTL3 Deficiency and 46. Protection Against Coronary Artery Disease. J Am Coll Cardiol. 2017;69(16):2054-63. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, 47 ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220-7. Kovrov O, Kristensen KK, Larsson E, Ploug M, Olivecrona G. On the mechanism of angiopoietin-like 48. 704705706707708707708709711712713715716717717717716717712712712722722372272protein 8 for control of lipoprotein lipase activity. J Lipid Res. 2019;60(4):783-93. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived 49. lipase that modulates HDL metabolism. Nat Genet. 1999;21(4):424-8. Cherukuri PF, Soe MM, Condon DE, Bartaria S, Meis K, Gu S, et al. Establishing analytical validity of 50. BeadChip array genotype data by comparison to whole-genome sequence and standard benchmark datasets. BMC Med Genomics. 2022;15(1):56. Stahl K, Gola D, König IR. Assessment of Imputation Quality: Comparison of Phasing and Imputation 51. Algorithms in Real Data. Front Genet. 2021;12:724037. Dewey FE, Gusarova V, O'Dushlaine C, Gottesman O, Trejos J, Hunt C, et al. Inactivating Variants in 52. ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016;374(12):1123-33. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in 53. APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of 54 lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001;98(13):7522-7. Walton RG, Zhu B, Unal R, Spencer M, Sunkara M, Morris AJ, et al. Increasing adipocyte lipoprotein 55. lipase improves glucose metabolism in high fat diet-induced obesity. J Biol Chem. 2015;290(18):11547-56. 56. Gobeil É, Bourgault J, Mitchell PL, Houessou U, Gagnon E, Girard A, et al. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. Eur Heart J. 2024;45(9):707-21. Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human 57. monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308-17. Thomas DG, Wei Y, Tall AR. Lipid and metabolic syndrome traits in coronary artery disease: a 58. Mendelian randomization study. J Lipid Res. 2021;62:100044.

- Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, et al. The impact of 59. partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circ Cardiovasc Genet. 2013;6(1):54-62.
- Zheng HF, Rong JJ, Liu M, Han F, Zhang XW, Richards JB, et al. Performance of genotype imputation 60. for low frequency and rare variants from the 1000 genomes. PLoS One. 2015;10(1):e0116487.
- Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S, et al. Searching for missing 61. heritability: designing rare variant association studies. Proc Natl Acad Sci U S A. 2014;111(4):E455-64. Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, et al. Exome sequencing of 62.
- Finnish isolates enhances rare-variant association power. Nature. 2019;572(7769):323-8.
- Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian randomisation to assess 63. potential benefit of clinical intervention. BMJ. 2012;345:e7325.
- 727728730731732733735736737738739740741742Henneman P, Aulchenko YS, Frants RR, van Dijk KW, Oostra BA, van Duijn CM. Prevalence and 64. heritability of the metabolic syndrome and its individual components in a Dutch isolate: the Erasmus Rucphen Family study. J Med Genet. 2008;45(9):572-7.
- Jonker JT, Smit JW, Hammer S, Snel M, van der Meer RW, Lamb HJ, et al. Dietary modulation of 65.
- plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am 743 J Clin Nutr. 2013;97(2):255-60.

744

## 745 APPENDICES

746	
747	Supplemental Note
748	This document contains the Supplemental Methods. The supplemental note .pdf also contains
749	Supplemental Figures 1–6.
750	
751	Supplemental Figures
752	<i>The Supplemental Figures 1–6 are contained within the supplemental note .pdf file.</i>
753	Supplemental Figure 1. Scatter plots showing the results of the drug-target MR analyses. Each
754	subplot represents the results of the analyses displayed in Figures 2-4 of the main manuscript that
755	used more than one genetic instrument.
756	Supplemental Figure 2. Regional genetic association plots showing the results of the
757	colocalization analyses. Each subplot represents the results of the analyses displayed in Figure 2-4 of
758	the main manuscript.
759	Supplemental Figure 3. Results of cis-pQTL MR analyses of the estimated glomerular filtration
760	rate by (eGFR) by Cystatin C and plasma Creatinine. The findings are displayed in bar graphs,
761	illustrating the level of the effect per s.d. decrease in protein abundance. The red lines represent the 95%
762	CI.
763	Supplemental Figure 4. Results of phenome-wide MR analysis on FinnGen outcomes using
764	ANGPTL3 rs34483103-1:62604866:AGTTAATGTG>A [3 prime UTR, c.*52_*60del] and APOC3
765	rs138326449-11:116830638:G>A [donor loss, c.55+1G>A] variants. A: Volcano plot displaying the
766	results of ANGPTL3 cis-pQTL phenome-wide MR. B: APOC3 cis-pQTL phenome-wide MR volcano
767	plot. The y-axis solid straight lines indicate the phenome-wide significance threshold. 'OR' indicates
768	the odds ratio with 95% confidence intervals with Bonferroni correction for the 694 FinnGen
769	outcomes.
770	Supplemental Figure 5. Cis-pQTL MR of the clinical laboratory outcomes, showing the results on
771	a 1-s.d. scale. The red bars indicate the 95 % CI. The black dots indicate the effect point estimate. '*'
772	indicate $P < 0.05$ . '**' indicates $P < 0.05$ with a shared causal variant (H <sub>4</sub> ). A list explaining the
773	abbreviations is provided in the supplemental material (Supplemental Table 1).
774	Supplemental Figure 6. Wildtype human ANGPTL4 protein and the ANGPTL4 E40K variant
775	protein are detected to a similar extent by the antibody used in the human ANGPTL4 ELISA.
776	Western blot of the precipitated medium of HEK293 cells transfected with expression vectors for
777	different mutant forms of human ANGPTL4 fused to a V5-tag (65). CC/AA is an oligomerization
778	defective ANGPTL4 variant. SDS-PAGE was performed using a loading buffer without DTT or other

779 disulfide-reducing agent. Equal amounts of medium were loaded. Membranes were blotted with an

- antibody from R&D Systems that is used for the human ANGPTL4 Elisa (AF3485, 1:2500). Secondary
- antibody was goat anti-rabbit IgG conjugated to HRP (1:5000).
- 782

## 783 Supplemental Tables

- 784 The Supplemental Tables 1-10 are located within the supplemental\_tables\_1\_10.xlsx file. The .xlsx file
- 785 is available via a public repository and can be accessed via the following link:
- 786 <u>https://doi.org/10.5281/zenodo.10880711</u>

## 787 Supplemental Table 1. Description of GWAS data sets

- 788 List of the GWAS data sets used. 'database.ID' denotes the EBI GWAS catalog identifiers if starting
- by "GCST", or the UK biobank showcase identifier if starting by a number.

## 790 Supplemental Table 2. MR results with 1000Genomes LD matrix

- Results of the MR analyses that are presented in the paper. 'rsids.dbsnp.ver144' denote the rsids that
- 792 were used in each MR model.

## 793 Supplemental Table 3. MR sensitivity analysis w. UKB 337K LD matrix vs. 1000Genomes.

- The Total Transformation of the Total Total
- matrices.'heterogeneity.statistic' indicates the heterogeneity P-value, which is described in detail in the
- supplemental note.
- 797 Supplemental Table 4. MR sample overlap risk of bias analysis
- 798 Result of the risk of bias from sample overlap analysis reporting the F-statistics, bias
- 799 ('Beta.bias.low.scenario', 'Beta.bias.medium.scenario', and 'Beta.bias.high.scenario') and type 1 error
- 800 inflation (Type1error.lowbias.scenario, Type1error.mediumbias.scenario,
- 801 Type1error.highbias.scenario) for each scenario and model.
- 802 Supplemental Table 5. ICD codes used for UKB lymphadenopathy-related phecodes
- 803 Phecode and ICD-codes as described in the Methods section.
- 804 Supplemental Table 6. ANGPTL4 p.40K pQTL MR PheWAS results
- 805 Detailed results of the MR analyses presented in Figure 4D.
- 806 Supplemental Table 7. ANGPTL4 p.Cys80fs pQTL MR PheWAS results
- 807 Detailed results of the MR analyses presented in Figure 4D.
- 808 Supplemental Table 8. ANGPTL3 rs34483103-1:62604866:AGTTAATGTG>A [3 prime UTR,
- 809 c.\*52\_\*60del] pQTL MR PheWAS results
- 810 Detailed results of the MR analyses presented in **Supplemental Figure 4A**.
- 811 Supplemental Table 9. APOC3 rs138326449-11:116830638:G>A [donor loss, c.55+1G>A] pQTL
- 812 MR PheWAS results
- 813 Detailed results of the MR analyses presented in **Supplemental Figure 4B**.
- 814 Supplemental Table 10. List of variants used in the UK Biobank genetic association analyses
- 815 'rsID' indicates the NCBI Reference SNP cluster ID. 'REVEL' denotes the Rare Exome Variant
- 816 Ensemble Learner pathogenicity prediction score for missense variants.